- Nasal challenge studies have shown that both histamine and cysteinyl
leukotrienes activate inflammation in allergic states, providing sound
biochemical reasoning for the use of LTs in allergic rhinitis.
- Further evidence, namely a dedicated equivalency study, needs be gathered
in order to replace H1 blockers with LTs as single-agent therapy for
- Though uncommon, a worrisome side effect profile may make LTs unfeasible
for the treatment of allergic rhinitis, especially in children.
- Meltzer E, Malmstrom K. Concomitant montelukast and loratadine as
treatment for seasonal allergic rhinitis. J Allergy Clin Immunol
- Pullerits T, Praks L. Randomized placebo-controlled study comparing
a leukotriene antagonist and a nasal glucocorticoid in seasonal allergic
rhinitis. Am J Respir Crit Care Med 1999; 159:1814-18.
- Meltzer E. Clinical evidence for antileukotriene therapy in the management
of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 88: 23-9.
- Krysan DJ, Kemper AL. Claims of equivalence in RCTs of the treatment
of bacterial meningitis in children. Pediatric Infectious Disease
Journal 2002; 21:753-8.